[go: up one dir, main page]

MA37894B1 - Protéines de fusion d'interleukine-2 et leurs utilisations - Google Patents

Protéines de fusion d'interleukine-2 et leurs utilisations

Info

Publication number
MA37894B1
MA37894B1 MA37894A MA37894A MA37894B1 MA 37894 B1 MA37894 B1 MA 37894B1 MA 37894 A MA37894 A MA 37894A MA 37894 A MA37894 A MA 37894A MA 37894 B1 MA37894 B1 MA 37894B1
Authority
MA
Morocco
Prior art keywords
fusion proteins
interleukin
methods
present
relates
Prior art date
Application number
MA37894A
Other languages
English (en)
Other versions
MA37894A1 (fr
Inventor
Ralf Hosse
Ekkehard Moessner
Pablo Umana
Christian Klein
Laurence Bernard Peterson
Linda Wicker
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48948417&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37894(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of MA37894A1 publication Critical patent/MA37894A1/fr
Publication of MA37894B1 publication Critical patent/MA37894B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne en général des protéines de fusion d'immunoglobulines et d'interleukine-2 (il-2). De plus, la présente invention concerne des polynucléotides codant pour de telles protéines de fusion, et des vecteurs et cellules hôtes comprenant de tels polynucléotides. L'invention concerne en outre des procédés de production des protéines de fusion de l'invention, et leurs procédés d'utilisation dans le traitement d'une maladie.
MA37894A 2012-08-10 2013-08-07 Protéines de fusion d'interleukine-2 et leurs utilisations MA37894B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261681676P 2012-08-10 2012-08-10
PCT/EP2013/066516 WO2014023752A1 (fr) 2012-08-10 2013-08-07 Protéines de fusion d'interleukine-2 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA37894A1 MA37894A1 (fr) 2018-07-31
MA37894B1 true MA37894B1 (fr) 2020-01-31

Family

ID=48948417

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37894A MA37894B1 (fr) 2012-08-10 2013-08-07 Protéines de fusion d'interleukine-2 et leurs utilisations

Country Status (22)

Country Link
US (4) US20140044675A1 (fr)
EP (1) EP2882458B1 (fr)
JP (1) JP6526561B2 (fr)
KR (1) KR20150041628A (fr)
CN (2) CN111635460A (fr)
AR (1) AR092089A1 (fr)
AU (1) AU2013301562B2 (fr)
BR (1) BR112015002765A2 (fr)
CA (1) CA2873291A1 (fr)
CL (1) CL2014003322A1 (fr)
CO (1) CO7121348A2 (fr)
CR (1) CR20140532A (fr)
EA (1) EA201500206A1 (fr)
HK (1) HK1208827A1 (fr)
IL (1) IL236933A0 (fr)
MA (1) MA37894B1 (fr)
MX (1) MX2015001749A (fr)
PE (1) PE20150752A1 (fr)
PH (1) PH12014502767A1 (fr)
SG (1) SG11201407579QA (fr)
TW (1) TW201420607A (fr)
WO (1) WO2014023752A1 (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3489255T3 (pl) 2011-02-10 2021-11-22 Roche Glycart Ag Zmutowane polipeptydy interleukiny-2
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CN105121715B (zh) 2012-12-11 2018-10-26 艾伯特叶史瓦大学爱因斯坦医学院 高通量受体:配体鉴定方法
NZ719654A (en) 2014-02-06 2020-06-26 Hoffmann La Roche Interleukin-2 fusion proteins and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MA40094B1 (fr) * 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
CN113234138A (zh) * 2014-08-11 2021-08-10 德里尼亚公司 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体
TR201901445T4 (tr) * 2015-08-06 2019-02-21 Agency Science Tech & Res Il2rbeta/yaygın gamma zinciri antikorları.
BR112018010937A2 (pt) 2015-12-04 2018-12-04 Novartis Ag composições de anticorpos enxertados com citocina e métodos de uso para imunorregulação
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR20190044029A (ko) 2016-05-18 2019-04-29 알버트 아인슈타인 컬리지 오브 메디슨, 인크. 변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법
AU2017268348A1 (en) 2016-05-18 2018-10-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3471754A1 (fr) 2016-06-20 2019-04-24 Kymab Limited Anticorps anti-pd-l1
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
MX2019005400A (es) 2016-11-08 2019-08-05 Delinia Inc Variantes de il-2 para el tratamiento de enfermedades autoinmunes.
CA3043630A1 (fr) 2016-12-22 2018-06-28 Cue Biopharma, Inc. Polypeptides multimeres modulateurs des lymphocytes t et leurs methodes d'utilisation
WO2018129474A1 (fr) 2017-01-09 2018-07-12 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
CN118453840A (zh) 2017-03-15 2024-08-09 库尔生物制药有限公司 用于调节免疫应答的方法
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
EA201992765A1 (ru) 2017-05-24 2020-03-25 Новартис Аг Белки на основе антител с привитым цитокином и способы их применения в лечении рака
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
EP3737692A4 (fr) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. Constructions de liaison à la calréticuline et lymphocytes t modifiés pour le traitement de maladies
WO2019139896A1 (fr) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
JP7534215B2 (ja) * 2018-01-24 2024-08-14 ベイジン パーカンズ オンコロジー カンパニー リミテッド サイトカイン融合タンパク質
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
MX2020009975A (es) 2018-03-28 2020-10-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
WO2020010250A2 (fr) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Molécules d'anticorps anti-tcr et leurs utilisations
WO2020007937A1 (fr) 2018-07-03 2020-01-09 Iltoo Pharma Utilisation de l'interleukine-2 pour le traitement de la sclérose systémique
WO2020035482A1 (fr) 2018-08-13 2020-02-20 Iltoo Pharma Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
WO2020127277A1 (fr) 2018-12-18 2020-06-25 Robert Koch-Institut Cellule présentatrice du cmh-i chargée de peptides et il-2 présentant une demi-vie prolongée pour amplifier une réponse immunitaire cytotoxique cellulaire
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
US12084484B2 (en) 2019-07-26 2024-09-10 Visterra, Inc. Interleukin-2 agents and uses thereof
WO2021138474A2 (fr) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Molécules d'anticorps anti-tcr et leurs utilisations
EP4103607A4 (fr) 2020-02-16 2023-12-20 Aulos Bioscience, Inc Anticorps anti-il-2 modifiés
AU2021230103A1 (en) 2020-03-06 2022-09-22 Assistance Publique - Hopitaux De Paris Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis
WO2021231376A2 (fr) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs méthodes d'utilisation
CN116323647A (zh) 2020-05-13 2023-06-23 博纳姆治疗公司 蛋白质复合物的组合物及其使用方法
CN113912734B (zh) * 2020-07-08 2025-02-28 南京师范大学 融合多肽及其用途
EP4211149A4 (fr) 2020-09-09 2024-10-09 Cue Biopharma, Inc. Polypeptides multimères modulateurs des lymphocytes t du cmh de classe ii pour le traitement du diabète sucré de type 1 (dt1) et leurs procédés d'utilisation
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022087458A1 (fr) 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions avec des molécules de liaison à l'antigène cd8 pour moduler la fonction de cellules immunitaires
CN112724259B (zh) * 2020-11-16 2022-12-20 天津林达生物科技有限公司 人血清白蛋白与白介素2的融合蛋白及其用途
EP4255466A1 (fr) 2020-12-04 2023-10-11 Visterra, Inc. Procédés d'utilisation d'agents d'interleukine-2
CN113248610B (zh) * 2021-05-14 2022-08-16 厦门柏慈生物科技有限公司 白细胞介素2结合分子、其衍生物、试剂盒及其生产方法和用途
WO2024008126A1 (fr) * 2022-07-06 2024-01-11 Elpiscience (Suzhou) Biopharma, Ltd. Mutéines d'il2 et leurs utilisations
CN117003852B (zh) * 2022-07-07 2024-11-05 北京大学 白细胞介素-2的拓扑改造及其作为自身免疫病药物的应用
CA3265946A1 (fr) 2022-09-12 2024-03-21 Sorbonne Universite Interleukine-2 pour le traitement des troubles du spectre autistique
KR20240055222A (ko) * 2022-10-19 2024-04-29 주식회사 에이프릴바이오 인터루킨-2 변이 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도
KR20250096834A (ko) * 2022-11-02 2025-06-27 베이징 창핑 래보러토리 융합 단백질 및 이의 용도
EP4615868A2 (fr) * 2022-11-10 2025-09-17 Aulos Bioscience, Inc Méthodes d'utilisation d'anticorps anti-il-2
EP4630035A1 (fr) 2022-12-05 2025-10-15 Centre Hospitalier Universitaire de Nimes Interleukine-2 humaine à faible dose pour traitement de la sclérose latérale amyotrophique dans un sous-groupe de patients
EP4648792A2 (fr) 2023-01-09 2025-11-19 Odyssey Therapeutics, Inc. Protéines de liaison à l'antigène anti-tnfr2 et leurs utilisations
WO2025217240A1 (fr) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Protéines de liaison à l'antigène anti-tnfr2 et leurs utilisations
WO2026006809A1 (fr) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Molécules multispécifiques se liant à tnfr2 et cd25 et leurs utilisations
CN120424884B (zh) * 2025-07-10 2025-11-04 上海惠盾因泰生物科技有限公司 表达分泌型il-2融合蛋白的工程化til及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7802170A (nl) 1977-04-18 1978-10-20 Hitachi Metals Ltd Sierraad.
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
WO1985000817A1 (fr) 1983-08-10 1985-02-28 Amgen Expression microbienne de l'interleukine ii
JPS60502136A (ja) * 1983-08-10 1985-12-12 アムジエン　インコーポレイテツド 微生物によるインタ−ル−キン２の形質発現
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
EP1034298B1 (fr) 1997-12-05 2011-11-02 The Scripps Research Institute Humanisation d'anticorps murins
CA2320403A1 (fr) * 1998-02-25 1999-09-02 Lexigen Pharmaceuticals Corporation Amelioration de la demi-vie circulante de proteines hybrides a base d'anticorps
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
ATE542137T1 (de) 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CA2557677A1 (fr) 2004-03-05 2005-10-06 Chiron Corporation Systeme de tests in vitro permettant de predire la tolerabilite d'agents therapeutiques chez des patients
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
HRP20130440T1 (en) 2004-04-13 2013-06-30 F. Hoffmann - La Roche Ag Anti-p-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US20060110398A1 (en) 2004-11-24 2006-05-25 Schering Corporation DAP-10 and uses thereof
AU2007271398B2 (en) * 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
AU2008278803A1 (en) 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binging agents directed to KDR and uses thereof - 035
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
US20110274650A1 (en) 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
MA34519B1 (fr) 2010-08-13 2013-09-02 Roche Glycart Ag Anticorps anti-fap et procédés d'utilisation
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
PL3489255T3 (pl) 2011-02-10 2021-11-22 Roche Glycart Ag Zmutowane polipeptydy interleukiny-2
ES2693645T3 (es) 2011-03-11 2018-12-13 Assistance Publique - Hôpitaux De Paris Uso de IL-2 a baja dosis para tratar la diabetes tipo 1
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP3626739A1 (fr) 2011-06-24 2020-03-25 Stephen D. Gillies Protéines de fusion d'immunoglobuline à chaîne légère et leurs procédés d'utilisation
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
NZ719654A (en) 2014-02-06 2020-06-26 Hoffmann La Roche Interleukin-2 fusion proteins and uses thereof
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
MX2015001749A (es) 2015-06-05
JP6526561B2 (ja) 2019-06-05
EA201500206A1 (ru) 2016-04-29
AU2013301562B2 (en) 2017-04-06
US10562949B2 (en) 2020-02-18
EP2882458A1 (fr) 2015-06-17
PE20150752A1 (es) 2015-05-15
WO2014023752A1 (fr) 2014-02-13
CN111635460A (zh) 2020-09-08
IL236933A0 (en) 2015-03-31
US11365232B2 (en) 2022-06-21
PH12014502767A1 (en) 2015-02-09
US20140044675A1 (en) 2014-02-13
US20160090407A1 (en) 2016-03-31
AU2013301562A1 (en) 2014-11-20
CN104507504A (zh) 2015-04-08
CA2873291A1 (fr) 2014-02-13
TW201420607A (zh) 2014-06-01
BR112015002765A2 (pt) 2018-03-13
US20180009868A1 (en) 2018-01-11
CO7121348A2 (es) 2014-11-20
CR20140532A (es) 2015-01-12
EP2882458B1 (fr) 2018-07-11
MA37894A1 (fr) 2018-07-31
US20200172591A1 (en) 2020-06-04
SG11201407579QA (en) 2014-12-30
CL2014003322A1 (es) 2015-02-13
JP2015530984A (ja) 2015-10-29
HK1208827A1 (en) 2016-03-18
KR20150041628A (ko) 2015-04-16
AR092089A1 (es) 2015-03-25

Similar Documents

Publication Publication Date Title
MA37894B1 (fr) Protéines de fusion d'interleukine-2 et leurs utilisations
MA20150232A1 (fr) Protéines de fusion de l'interleukine-10 et leurs utilisations
MA39250B1 (fr) Protéines hybrides de l'interleukine-2 et leurs utilisations
MA38406B1 (fr) Virus de la maladie de newcastle et leurs utilisations
PH12017501583A1 (en) Novel proteins specific for cd137
SA521422581B1 (ar) أil-7r جسام مضادة للوحدة الثانوية ألفا واستخداماتها
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MX378747B (es) Complejos de proteínas de citomegalovirus.
MA38308B1 (fr) Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t
EP4403570A3 (fr) Anticorps anti-il-33 et leurs utilisations
EA201270713A1 (ru) Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
MA35130B1 (fr) Composition comprenant de l'aflibercept, de l'acide folinique, du 5-fluoro-uracile (5-fu) et de l'irinocetan (folfiri)
MX384075B (es) Nuevas proteínas específicas para la angiogénesis.
PH12014502184A1 (en) Anti-hla-b* 27 antibodies and uses thereof
SMAP201100010A (it) Composizioni e metodi di uso di anticorpi terapeutici.
BR112014026755B8 (pt) anticorpos contra claudin 18.2 úteis no diagnóstico de câncer
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
MX2015005384A (es) Miembros de union para il-1 beta.
MA40283A (fr) Aptamères spécifiques du récepteur tlr-4 et leurs utilisations
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
EP4467566A3 (fr) Bac d'anticorps de chimiokines elr+cxc
MA35935B1 (fr) Oligonucléotides pour moduler l'expression de gènes et leurs utilisations
CY1116962T1 (el) Ανθρωπινες λευκολεκτινες και χρησεις αυτων
FR2986229B1 (fr) Nouveaux monergols ioniques a base de n2o pour la propulsion spatiale